Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 October 2020 | Story Lacea Loader

The Free State is currently one of the provinces in the country with the highest percentage of new tests that turn out positive for COVID-19. This also impacts on the staff and students at the University of the Free State (UFS), as the number of positive cases on the campuses has increased considerably during the past few weeks.  

The UFS experienced an increase of 47% in the number of students who tested positive from Level 2 of the national lockdown to Level 1. During the past few days, an increase of 21% in positive student cases has been experienced. In the case of staff, an increase of 34% in the number who tested positive occurred from Level 2 of the national lockdown to Level 1. Over  the past few days, an increase of 11% in positive cases has been experienced.

1. Adherence to national protocols and regulations

The safety, health, and well-being of staff and students remain a priority. Therefore, the university management is concerned about the rise in positive cases on the campuses and appeals to staff to adhere to the national protocols and regulations issued by the Ministers of Cooperative Governance and Traditional Affairs, Employment and Labour, Higher Education, Science and Innovation, and Health.   

It is important to note that non-adherence to certain of the national protocols and regulations is a criminal offence and is punishable by a fine or imprisonment of up to six months. By not adhering to national protocols and regulations, our staff is not only putting their own health at risk, but also the health of others.

2. Behaviour observed on campus  

The following behaviour has been observed among staff working on campus:
- Not adhering to social/physical distancing of 2 metres;
- Face-to-face contact without wearing masks (e.g. in boardrooms and tearooms, visiting each other in offices, etc);
- Not wearing a mask while moving on campus, as well as in buildings (except in the privacy of offices);
- Dishonesty during the screening process; and
- Non-compliance with isolation and quarantine guidelines.
Staff members are reminded that they may face disciplinary action if they do not adhere to the national COVID-19 protocols and regulations as issued by the different ministers. It is important that staff members be honest at all times during the screening process, as it has been observed that some staff members display some COVID-19-related symptoms but answer in the negative on the online screening app.

3. Reporting of positive COVID-19 cases
In terms of the directives issued by the Minister of Employment and Labour, the Minister of Health, and the Minister of Higher Education, Science and Innovation, the UFS is required to report all COVID-19 positive cases to the Department of Labour, the Department of Health, and the Department of Higher Education and Training.  All COVID-19 positive cases must thus be reported directly to the Senior Director: Human Resources (vjaarsj@ufs.ac.za) and Kovsie Health (johnr@ufs.ac.za) for further handling and reporting to the relevant government departments.

Please do not come to the campuses if you are experiencing any COVID-19-related symptoms and get tested as soon as possible.

Those staff members who test positive will receive the necessary advice from their medical practitioners and they can also contact Kovsie Health for assistance.


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept